AGÕæÈ˹ٷ½

STOCK TITAN

ICON Announces Results of Annual General Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the .

Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions:

RESOLUTION NUMBER

RESOLUTION

Ìý Ìý

TOTAL
NUMBER OF
VOTES

Ìý Ìý

VOTE FOR

Ìý Ìý

VOTE
AGAINST

Ìý Ìý

VOTE
WITHHELD

Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý

1.1

Ìý

To re-elect Mr. Ciaran Murray

Ìý

Ìý

59,889,939

Ìý

Ìý

58,573,183

Ìý

Ìý

1,307,430

Ìý

Ìý

9,326

1.2

Ìý

To re-elect Dr. Steve Cutler

Ìý

Ìý

59,889,939

Ìý

Ìý

59,259,952

Ìý

Ìý

619,506

Ìý

Ìý

10,481

1.3

Ìý

To re-elect Mr. Rónán Murphy

Ìý

Ìý

59,889,939

Ìý

Ìý

58,434,915

Ìý

Ìý

1,444,942

Ìý

Ìý

10,082

1.4

Ìý

To re-elect Dr. John Climax

Ìý

Ìý

59,889,939

Ìý

Ìý

59,225,431

Ìý

Ìý

653,519

Ìý

Ìý

10,989

1.5

Ìý

To re-elect Ms. Julie O’Neill

Ìý

Ìý

59,889,939

Ìý

Ìý

59,342,873

Ìý

Ìý

536,081

Ìý

Ìý

10,985

1.6

Ìý

To re-elect Mr. Eugene McCague

Ìý

Ìý

59,889,939

Ìý

Ìý

59,261,955

Ìý

Ìý

614,569

Ìý

Ìý

13,415

1.7

Ìý

To re-elect Dr. Linda Grais

Ìý

Ìý

59,889,939

Ìý

Ìý

58,644,816

Ìý

Ìý

1,234,062

Ìý

Ìý

11,061

1.8

Ìý

To re-elect Ms. Anne Whitaker

Ìý

Ìý

59,889,939

Ìý

Ìý

59,540,334

Ìý

Ìý

338,444

Ìý

Ìý

11,161

2

Ìý

To review the Company’s affairs and consider the Accounts and Reports

Ìý

Ìý

59,889,939

Ìý

Ìý

59,572,121

Ìý

Ìý

248,388

Ìý

Ìý

69,430

3

Ìý

To ratify the appointment of EY as the Auditors of the Company and to authorise the Board, acting through its Audit Committee, to fix the Auditors� Remuneration

Ìý

Ìý

59,889,939

Ìý

Ìý

58,828,444

Ìý

Ìý

1,052,792

Ìý

Ìý

8,703

4

Ìý

To authorise the Company to allot shares

Ìý

Ìý

59,889,939

Ìý

Ìý

58,121,368

Ìý

Ìý

1,758,940

Ìý

Ìý

9,631

5**

Ìý

To disapply the statutory pre-emption rights

Ìý

Ìý

59,889,939

Ìý

Ìý

58,763,717

Ìý

Ìý

1,112,056

Ìý

Ìý

14,166

6**

Ìý

To disapply the statutory pre-emption rights for funding capital investment or acquisitions

Ìý

Ìý

59,889,939

Ìý

Ìý

57,957,914

Ìý

Ìý

1,919,567

Ìý

Ìý

12,458

7

Ìý

To authorise the Company and any subsidiary of the Company to make overseas market purchases of shares

Ìý

Ìý

59,889,939

Ìý

Ìý

59,470,630

Ìý

Ìý

380,237

Ìý

Ìý

39,072

Ìý

8**

Ìý

To authorise the price range at which the Company can reissue shares that it holds as treasury shares

Ìý

Ìý

59,889,939

Ìý

Ìý

59,269,086

Ìý

Ìý

576,246

Ìý

Ìý

44,607

** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.

About ICON plc

ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 39,900 employees in 95 locations in 55 countries as at June 30, 2025. For further information about ICON, visit: .

This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at .

ICON/ICLR-F

Investor Relations +1 888 381 7923

Nigel Clerkin Chief Financial Officer +353 1 291 2000

Kate Haven Vice President Investor Relations +1 888 381 7923

All at ICON

Source: ICON plc

ICON PLC

NASDAQ:ICLR

ICLR Rankings

ICLR Latest News

ICLR Latest SEC Filings

ICLR Stock Data

11.57B
78.96M
0.61%
98.56%
2.09%
Diagnostics & Research
Healthcare
Ireland
Dublin